Cellectar Biosciences Inc. (NASDAQ: CLRB) enrolled the first patient in a Phase 1b clinical trial of CLR 125, an experimental ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE